Blood-based DNA methylation biomarkers for type 2 diabetes : potential for clinical applications by Willmer, Tarryn et al.
REVIEW
published: 04 December 2018
doi: 10.3389/fendo.2018.00744
Frontiers in Endocrinology | www.frontiersin.org 1 December 2018 | Volume 9 | Article 744
Edited by:
Anna Alisi,
Bambino Gesù Ospedale Pediatrico
(IRCCS), Italy
Reviewed by:
Angela Lombardi,
Albert Einstein College of Medicine,
United States
Ashraf Al Madhoun,
Dasman Diabetes Institute, Kuwait
*Correspondence:
Tarryn Willmer
tarryn.willmer@mrc.ac.za
Specialty section:
This article was submitted to
Diabetes,
a section of the journal
Frontiers in Endocrinology
Received: 01 October 2018
Accepted: 23 November 2018
Published: 04 December 2018
Citation:
Willmer T, Johnson R, Louw J and
Pheiffer C (2018) Blood-Based DNA
Methylation Biomarkers for Type 2
Diabetes: Potential for Clinical
Applications. Front. Endocrinol. 9:744.
doi: 10.3389/fendo.2018.00744
Blood-Based DNA Methylation
Biomarkers for Type 2 Diabetes:
Potential for Clinical Applications
Tarryn Willmer 1*, Rabia Johnson 1,2, Johan Louw 1,3 and Carmen Pheiffer 1,2
1 Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg, South Africa, 2Division
of Medical Physiology, Faculty of Health Sciences, Stellenbosch University, Tygerberg, South Africa, 3Department of
Biochemistry and Microbiology, University of Zululand, Kwa-Dlangezwa, South Africa
Type 2 diabetes (T2D) is a leading cause of death and disability worldwide. It is a
chronic metabolic disorder that develops due to an interplay of genetic, lifestyle, and
environmental factors. The biological onset of the disease occurs long before clinical
symptoms develop, thus the search for early diagnostic and prognostic biomarkers,
which could facilitate intervention strategies to prevent or delay disease progression,
has increased considerably in recent years. Epigenetic modifications represent important
links between genetic, environmental and lifestyle cues and increasing evidence implicate
altered epigenetic marks such as DNA methylation, the most characterized and widely
studied epigenetic mechanism, in the pathogenesis of T2D. This review provides an
update of the current status of DNA methylation as a biomarker for T2D. Four databases,
Scopus, Pubmed, Cochrane Central, and Google Scholar were searched for studies
investigating DNA methylation in blood. Thirty-seven studies were identified, and are
summarized with respect to population characteristics, biological source, and method of
DNA methylation quantification (global, candidate gene or genome-wide). We highlight
that differential methylation of the TCF7L2, KCNQ1, ABCG1, TXNIP, PHOSPHO1,
SREBF1, SLC30A8, and FTO genes in blood are reproducibly associated with T2D
in different population groups. These genes should be prioritized and replicated in
longitudinal studies across more populations in future studies. Finally, we discuss
the limitations faced by DNA methylation studies, which include including interpatient
variability, cellular heterogeneity, and lack of accounting for study confounders. These
limitations and challenges must be overcome before the implementation of blood-based
DNA methylation biomarkers into a clinical setting. We emphasize the need for
longitudinal prospective studies to support the robustness of the current findings of this
review.
Keywords: global DNA methylation, gene-specific DNA methylation, genome-wide DNA methylation, blood, type
2 diabetes, biomarkers
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INTRODUCTION
Diabetes mellitus is a leading cause of death and disability
worldwide, affecting 415 million people in 2017, and this figure
is expected to increase to 592 million by 2035 (1, 2). Type 2
diabetes (T2D) accounts for over 90% of diabetes mellitus cases
and its incidence is increasing globally in response to escalating
rates of obesity and insulin resistance. Indeed, according to the
World Health Organization, over 90% of patients with T2D
are overweight or obese (3). T2D is a progressive, chronic
disorder with a long asymptomatic phase. The early stages of
disease can remain undetected for many years, during which
time micro- and macro-vascular complications may occur (4,
5). Identification of individuals during the asymptomatic phase
would not only permit opportunities for early interventions to
prevent the development of overt diabetes, but may also lead
to better management of the disease. A major area of current
research has thus been to search for robust, sensitive, and
readily accessible biomarkers of T2D. In this regard, a striking
amount of evidence has accumulated to suggest that changes
to the epigenetic landscape in insulin-responsive tissues play an
important role in the pathogenesis of obesity, insulin resistance,
and T2D, and if reflected in blood, may represent potential
biomarker candidates (6–8).
Epigenetics is defined as heritable changes that affect gene
expression without altering the underlying genomic sequence
(9). These processes include DNA methylation, chromatin
Abbreviations: T2D, Type 2 diabetes; FFAs, free fatty acids; 5mC, 5-
methylcytosine; CpG, Cytosine-guanine dinucleotides; GWAS, genome-wide
association studies; ELISA, enzyme-linked immunosorbent assay; HDL, high-
density lipoprotein; NOS3, nitric oxide synthase 3; LINE-1, long interspersed
nuclear element-1; LDL, low-density lipoprotein; Alu, Arthrobacter luteus;
MeDIP, methylated DNA immunoprecipitation; FTO, obesity-associated protein;
PPARγ, peroxisome proliferator–activated receptor gamma; PDK4, pyruvate
dehydrogenase lipoamide kinase isozyme 4; GCK, glucokinase; PRCKZ, protein
kinase C zeta; GIPR, gastric inhibitory polypeptide receptor; IGFNP-7, insulin-
like growth factor-binding protein 7; PTPN1, protein tyrosine phosphatase, non-
receptor type 1; MCP-1, monocyte chemoattractant protein-1; SLC30A8, solute
carrier family 30 member 8; BCL11A, B-cell lymphoma/leukemia 11A; TCF7L2,
transcription factor 7-like 2; CALM2, calmodulin 2; CRY2, CRY2 cryptochrome
circadian regulator 2; CMAK1D, Ca2+/calmodulin-dependent protein kinase 1
subfamily of serine/threonine kinases; TLR2, toll-like receptor 2; TLR3, toll-
like receptor 3; FFAR3, free fatty acid receptor 3; PI3K, phosphatidylinositol 3-
kinase; GLUT4, glucose transporter type 4; SNP, single nucleotide polymorphisms;
HOMA-IR, homeostatic model assessment for insulin resistance; ROS, reactive
oxygen species; GI, gastrointestinal; BMI, body mass index; SCFA, short chain
fatty acids; FFARs, free fatty acid receptors; OGTTs, oral glucose tolerance tests;
KCNQ1, potassium voltage-gated channel subfamily KQT member 1; THADA,
thyroid adenoma associated protein; JAZF1, juxtaposed with another zinc finger
protein 1; TXNIP, thioredoxin-interacting protein; ABCG1, ATP-binding cassette
sub-family G member 1; PHOSPHO1, phosphoethanolamine/phosphocholine
phosphatase 1; SOCS3, suppressor of cytokine signaling 3; SREBF1, sterol
regulatory element-binding transcription factor 1; HbA1c, hemoglobin A1c;
VEGF, vascular endothelial growth factor; DQX1, DEAQ-box RNA dependent
ATPase 1; SAMD12, Sterile AlphaMotif Domain Containing 12; MALT1, mucosa-
associated lymphoid tissue lymphoma translocation protein 1; GPR6, G-protein
receptor 6; TG, triglyceride; BCL3, B-Cell CLL/Lymphoma 3; IL23A, Interleukin
23 Subunit Alpha; F2RL1, F2R Like Trypsin Receptor 1; S100A12, S100 Calcium
Binding Protein A12; TNFRSF10B, TNF Receptor Superfamily Member 10b;
NEK6, NIMA Related Kinase 6; RNF31, Ring Finger Protein 31; SLC35B2, Solute
Carrier Family 35 Member B2; IRAK1BP1, Interleukin 1 Receptor Associated
Kinase 1 Binding Protein 1.
modifications such as histone acetylation and methylation, and
non-coding RNAs that act as regulatory molecules (9). DNA
methylation is the most widely studied and best characterized
epigenetic mechanism, and involves the covalent addition of a
methyl group to carbon C5 of cytosine nucleotides to create
5-methylcytosine (5 mC) (10). Cytosine methylation occurs in
cytosine-guanine dinucleotides (CpG) sites, which tend to cluster
together as repetitive sequences known as CpG islands, which
are primarily found within promoter regions of genes, or regions
with increased centromeric tandem repeat units (9, 10). CpG
methylation within promoter regions is generally associated with
gene silencing, although recent studies have provided evidence of
the importance of non-CpG and non-promoter methylation in
development and disease (11, 12). DNA methylation alterations
can occur in response to biological (13, 14), lifestyle (15,
16), and environmental (17) factors and associate with gene
expression changes and pathological dysfunctions. Moreover,
DNA methylation is reversible, and therefore aberrant DNA
methylation modifications have attracted increased interest as
drug targets. As such, the interest in dissecting the impact of
epigenetic variation on human diseases, including T2D, has
increased over the last decade (18–23).
For numerous epidemiological studies, it is not always
possible to access human tissues central to the pathogenesis of
disease. Importantly, T2D-associated DNA methylation changes
in pancreatic ß-cells and insulin-responsive tissues (liver, muscle,
and adipose tissue) have been reported to be reflected in the
blood, thus offering an opportunity to use alternative, non-
invasive clinical samples for methylation analysis (7, 8, 24).
Peripheral blood is relatively quick and easy to collect, with
minimal side effects and much higher patient acceptability. As
blood collection is already a part of routine medical checkups
in both developed and developing countries, identification of
blood-based DNAmethylation alterations would greatly facilitate
biomarker discovery for T2D screening. This, together with the
chemical and biological stability of DNA methylation signatures,
mark them as attractive and feasible prognostic/diagnostic tools.
Despite the exponential rise in epigenetic research over the
last decade, the current status of DNA methylation alterations
in blood from human T2D subjects still remains limited.
Indeed, most recent reviews have focused on DNA methylation
signatures in pancreatic islets and peripheral tissues (liver,
skeletal muscle, and adipose tissue), which are not feasible tissue
sources for biomarker generation. The aim of this review is
to summarize, discuss, and integrate the most recent available
evidence of the potential of blood-based DNA methylation
alterations as candidate biomarkers for T2D prevention and
treatment.
Four databases, Scopus, PubMed, Cochrane Central, and
Google Scholar, were searched to identify published studies
reporting DNA methylation changes in blood between January
2008 to July 2018. The following keywords: “DNA methylation,”
AND “blood,” OR “peripheral blood,” OR “peripheral blood
mononuclear cells,” OR “peripheral blood leukocytes” OR
“peripheral blood lymphocytes” OR “white blood cells” AND
“type 2 diabetes” AND “human” were used. Studies were
considered eligible if they were original articles, investigated
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DNA methylation patterns in relationship with T2D and
if the study was published in English. Reference lists of
included studies were also hand-searched to identify other
potentially eligible studies. Both cross-sectional, case control, and
longitudinal studies that provided sufficient information were
included. The study methods included global DNA methylation
studies, candidate-gene methylation studies, and genome-wide
association studies (GWAS).
GLOBAL DNA METHYLATION STUDIES
Global DNA methylation, referred to as the total methylation
status that occurs across the genome, has been reported to be
one of the earliest molecular changes in the transition of a cell
from a normal to a diseased state (25). Technological advances
have resulted in an increase in global DNA methylation studies.
Current methods to quantify global DNA methylation include
enzyme-linked immunosorbent assays (ELISA), methylation-
sensitive restriction enzymes, liquid chromatography coupled
with mass spectrometry, flow cytometry, and quantification
of DNA methylation within repetitive elements using bisulfite
pyrosequencing (26). Global DNA methylation studies are
advanced in cancer research, with a blood-based candidate
diagnostic biomarker for colorectal cancer already commercially
available (27). In recent years, global DNA has attracted
considerable interest as a biomarker for T2D. Studies that have
quantified global DNA methylation in peripheral blood of T2D
subjects are summarized in Table 1.
Luttmer et al. quantified global DNA methylation levels
in peripheral blood leukocytes of 738 individuals from the
Netherlands Hoorn Study cohort and reported a progressive
decrease in global DNA methylation in individuals with
T2D compared to those with impaired glucose tolerance and
normoglycaemia. Moreover, DNA hypomethylation in these
subjects was independently associated with hyperglycaemia and
high-density lipoprotein (HDL) cholesterol (28). In contrast, a
Colombian study using a smaller patient group, observed a global
increase in DNA methylation in 44 subjects with T2D compared
to 35 healthy controls, which correlated with the percentage of
glycated hemoglobin A1c (HbA1c) (29). Similar findings were
reported by Matsha et al. using a South African population
consisting of 158 individuals with T2D, 119 with dysglycaemia,
and 287 healthy controls. They showed that levels of global DNA
methylation were higher in individuals with impaired glucose
tolerance or treatment-naïve T2D compared to those with
normoglycaemia (29, 30). Interestingly, no difference in global
DNA methylation was observed between diabetic individuals on
treatment and normoglycaemic subjects, prompting the authors
to speculate that glucose management caused the reversal of
aberrant DNA methylation patterns during T2D (30).
An innovative study by Simar et al. measured global DNA
methylation levels of different subtypes of peripheral blood
mononuclear cells in obese and T2D individuals, using a
flow cytometry bead-based method. They reported that global
DNA methylation levels were increased in B cells from obese
individuals and subjects with T2D, and in natural killer
lymphocytes from patients with T2D, while no overall difference
was observed in themixed population of bloodmononuclear cells
from these individuals. DNA methylation in B cells and natural
killer lymphocytes correlated positively with insulin resistance,
suggesting an association between DNA methylation alterations,
immune function, and metabolic disorders (31). These findings
highlight the importance for not only tissue specific but also cell
type specific epigenetic studies, which may improve sensitivity
and specificity.
Repetitive elements, such as long interspersed nuclear element-
1 (LINE-1) are highly represented throughout the genome and
as such, methylation of these elements is generally considered
to correlate with global genomic DNA methylation (38).
Martin-Núñez (33) demonstrated that LINE-1 methylation was
decreased in peripheral blood from a small Spanish group
of 12 individuals with T2D compared to 12 normoglycaemic
individuals (33). Conversely, a study using 228 non-diabetic
individuals reported that LINE-1 DNA hypermethylation is
associated with increasing fasting glucose, total cholesterol,
triglycerides, low-density lipoprotein (LDL) cholesterol, and risk
of developing T2D (34). These findings were later supported by
Wu and colleagues who reported a significant increase in LINE-
1 methylation in a group of 205 Chinese patients with T2D
compared to 213 healthy controls (35). Using a similar approach,
Zhao and colleagues assessed methylation of Arthrobacter luteus
(Alu) elements as a proxy for global DNA methylation by
performing quantitative bisulfite pyrosequencing. They found
that hypermethylation of these elements in peripheral blood
leukocytes from 84 monozygotic twin pairs discordant for T2D
was significantly associated with insulin resistance (36). More
recently, Alu methylation levels were also investigated in white
blood cells from 85 individuals with T2D, 113 with impaired
glucose tolerance, and 42 healthy control subjects, using Alu-
Combined Bisulfite Restriction Analysis (COBRA). Interestingly,
in contrast to the findings of Zhao et al. (36), they reported
that individuals with T2D exhibited the lowest Alu methylation
compared to controls, which directly correlated with higher
fasting blood glucose and HbA1c concentrations and high blood
pressure (37). Taken together, the results from global DNA
methylation analysis are mostly inconsistent and more studies
are needed to consolidate the findings on the association between
blood-based global DNA methylation and T2D.
CANDIDATE GENE STUDIES
Despite being a robust measure of overall genomic methylation,
global DNA does not have the resolution to measure methylation
within specific genes (39). Thus, a candidate gene approach
to quantify the methylation status of specific CpG sites within
genes associated with T2D are increasingly being investigated
(40). Methods used in these studies include methylated DNA
immunoprecipitation (MeDIP), methylation specific PCR, mass
spectrometry combined with RNA base-specific cleavage, as
well as bisulfite pyrosequencing (41). Genes investigated include
fat mass and obesity-associated protein (FTO), peroxisome
proliferator–activated receptor gamma (PPARγ ), pyruvate
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dehydrogenase lipoamide kinase isozyme 4 (PDK4), transcription
factor 7-like 2 (TCF7L2), monocyte chemoattractant protein-1
(MCP-1), glucokinase (GCK), protein kinase C zeta (PRCKZ),
B-cell lymphoma/leukemia 11A (BCL11A), gastric inhibitory
polypeptide receptor (GIPR), solute carrier family 30 member 8
(SLC30A8), insulin-like growth factor-binding protein 7 (IGFNP-
7), protein tyrosine phosphatase, non-receptor type 1 (PTPN1),
calmodulin 2 (CALM2), CRY2 cryptochrome circadian regulator 2
(CRY2), Ca2+/calmodulin-dependent protein kinase 1 subfamily
of serine/threonine kinases (CAMK1D), toll-like receptor (TLR) 2,
and 4, and free fatty acid receptor 3 (FFAR3), which are discussed
in further detail below and summarized in Table 2
Genes Involved in Glucose and Lipid
Metabolism
The FTO gene encodes a 2-oxoglutarate-dependent nucleic acid
demethylase and various studies have reported that variants
in the FTO locus are strongly linked with obesity and can
predict risk of T2D and cardiovascular disease (53–57). The
methylation status of FTO was analyzed by van Otterdijk
et al. who identified hypermethylation of one CpG locus in
the promoter region in peripheral blood leukocytes from 25
individuals with T2D compared to 11 control healthy subjects
(40). The same study also identified hyper- and hypomethylation
of CpG sites in the promoters of the PPARγ and PDK4 genes,
respectively, in patients with T2D vs. healthy controls. PPARγ
is a transcription factor that plays major roles in adipogenesis
and insulin sensitivity, and agonists are currently being used as
anti-diabetic agents (58). PDK4 is reported to play a role in the
regulation of glucose metabolism and mitochondrial function,
and hypomethylation of this gene has also been reported in
skeletal muscle of diabetic patients compared to controls (59).
TCF7L2 is involved in glucose homeostasis and was reported to
be differentially methylated in 13 of its promoter CpGs (eight
hypermethylated and five hypomethylated) between treatment-
naïve patients with T2D andmatched controls (42). Furthermore,
methylation at specific CpG sites of the TCF7L2 promoter
correlated significantly with fasting glucose concentrations, total
cholesterol, LDL-cholesterol, as well as the homeostatic model
assessment for insulin resistance (HOMA-IR) (47).
MCP-1 is a chemokine that regulates macrophage migration
and infiltration into adipose tissue and in this way, contributes to
insulin resistance and decreased glucose uptake during obesity
and T2D (60). Interestingly, hypomethylation of the MCP-1
promoter associated with increased serumMCP-1 levels, HbA1c,
and fasting blood glucose levels in patients with T2D compared
to healthy controls (43). The GCK gene encodes glucokinase,
a key glycolytic enzyme that catalyzes the first step in hepatic
and pancreatic islet glucose utilization pathways (61). Tang
et al. (44) evaluated GCK methylation in T2D subjects and
matched controls, and identified significant hypermethylation
of one intragenic CpG site exclusively in male patients with
T2D compared to healthy controls, which also correlated with
total cholesterol levels. The results for this association indicate
an interaction between gender and T2D-associated methylation
alterations.
Genes Involved in Insulin Secretion and
Function
PRKCZ, a member of the PKC family of serine/threonine
kinases, functions downstream of phosphatidylinositol 3-kinase
(PI3K) to positively regulate the insulin signaling pathway and
contributes to the translocation of glucose transporter type
4 (GLUT4) from the cytoplasm to the membrane, where it
facilitates glucose uptake (62). A comparison between the PRKCZ
promoter sequence in peripheral blood leukocytes from Chinese
individuals with either T2D or normoglycaemia showed that
seven CpG sites were methylated in the T2D group whereas
only one CpG site was methylated in the control group (45).
Furthermore, the protein expression levels of PRKCZ in the
serum of the group with T2Dwas significantly reduced compared
to the control group, suggesting that PRKCZ promoter activity
and gene expression are regulated by methylation (45). The
BCL11A gene, encoding a CH2H2 type zinc-finger transcription
factor, has also been associated with T2D risk. BCL11A plays a
normal physiological role in lymphocyte production but variants
of this gene have been shown to affect insulin response to glucose,
as well glucagon secretion (63, 64). Tang et al. investigated the
correlation between BCL11A methylation at one intragenic and
four promoter CpG sites and T2D risk (46). They found a
significant decrease in the mean DNA methylation levels across
these CpG sites in males with T2D compared to normoglycaemic
controls (46). Interestingly, these differences were not observed
in females.
The GIPR gene encodes a receptor of the incretin, GIP, a
gastrointestinal hormone that stimulates insulin response after
ingesting food. Canivell et al. performed DNA methylation
profiling of the GIPR promoter in peripheral blood DNA
and identified differential methylation at nine CpG sites
located upstream of the first exon between patients with
T2D and controls. On average, these nine CpG sites were
hypomethylated in patients with T2D and significantly correlated
with waist circumference and fasting glucose concentrations (47).
SLC30A8 encodes a pancreas-specific, zinc eﬄux transporter, and
reduced levels or activity of SLC30A8 hinder glucose-induced
insulin secretion, as zinc is required for the crystallization of
insulin within secretory granules (65). Seman et al. analyzed
DNA methylation alterations in the SLC30A8 promoter in
peripheral blood from a large Malay population and identified
hypermethylation of five CpG sites in patients with T2D
compared to controls (48).
Another insulin associated gene that has been linked to T2D
is IGFBP-7, a member of the insulin growth factor binding
family. The expression of IGFBP-7 was previously found to
be increased in the serum of subjects with T2D compared
to controls, and significantly associated with insulin resistance
(49, 66, 67). Gu et al. studied the correlation between IGFBP-7
promoter methylation and T2D in peripheral blood from a large
Swedish cohort of subjects. They identified increased IGFBP-7
methylation in three CpG sites in newly diagnosed men with
T2D, but not in women, compared to non-diabetic individuals
(49). Interestingly, no significant differences in serum IGFBP-7
expression were observed between groups (49). These results are
conflicting with previous studies that reported increased serum
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IGFBP-7 concentrations in T2D subjects compared to healthy
individuals. The discrepancies in these results may be due to
the use of a much larger sample size in the study by Gu et al.
(140 T2D subjects and 100 controls), as well as differences in the
selection criteria of the patients with T2D between studies (49,
66, 67). While Gu et al. (49) studied newly diagnosed, treatment
naïve T2D subjects, the previous studies included participants
on chronic pharmacological therapies, including insulin, oral
hypoglycaemic agents, statins, fibrates, blood pressure–lowering
agents, and aspirin (49, 66, 67).
More recently, Huang et al. investigated the methylation
status of another key regulator of the insulin signaling pathway,
PTPN1, in relation to T2D susceptibility (50). PTPN1 encodes
the protein-tyrosine phosphatase 1B protein, which attenuates
the insulin signaling pathway by decreasing the phosphorylation
of the insulin receptor and/or insulin receptor substrate 1 (68).
In the study, DNA methylation of the PTPN1 promoter region
was quantified in peripheral blood mononuclear cells from 97
Chinese patients with T2D and 97 age- and gender-matched
healthy controls, using bisulfite pyrosequencing. The results
revealed a significant correlation between PTPN1 promoter
methylation and increased T2D risk in females, but not in
males. Furthermore, PTPN1 methylation was also inversely
associated with low-density lipoprotein and total cholesterol
levels in females. These results indicate that PTPN1 promoter
hypermethylation is a risk factor for T2D in the female Chinese
population.
Genes Associated With Pancreatic and
Cardiovascular Function
Cheng et al. investigated DNA methylation in the promoters
of CALM2, CRY2, and CAMK1D, based on previous reports
linking variants of these genes with T2D susceptibility (51).
They demonstrated that four, five, and nine CpGs within the
CALM2, CRY2, and CAMK1D gene promoters, respectively,
were significantly hypomethylated in the peripheral blood of
subjects with T2D compared to healthy controls. CRY2 plays a
role in circadian rhythm which, when desynchronized, results
in metabolic disturbances including increased insulin and
postprandial glucose levels, increased arterial blood pressure,
and decreased leptin levels, which may predispose individuals
to T2D (69). Variants in the CALM2 gene, a member of the
calmodulin family, have been associated with dialysis survival in
T2D-associated renal disease, as well as arrhythmia susceptibility
in infants (70). CAMK1D plays a key role in granulocyte
function and reactive oxygen species (ROS) inhibition through
the chemokine signal transduction pathway, and consequently,
non-functional variants or hypomethylation of this gene may
result in apoptosis and consequently, reduced β-cell mass (71).
Genes Associated With Gut Microbiota
Remely et al. investigated DNA methylation of two genes
involved in innate immunity and inflammation, TLR 2, and 4, in
response to changes in gut microbiota in individuals with T2D
(72–74). This investigation was prompted by a spate of recent
studies to show that changes in gut microbiota composition
can lead to chronic low-grade inflammation, metabolic
dysregulation, and T2D (75, 76). Remely et al. investigated
three groups of subjects: patients with T2D using glucagon-like
peptide-1 (GLP-1) agonist therapy, obese individuals without
established insulin resistance, and a normal-weight control
group. The authors identified four significantly hypomethylated
CpGs in the first exon of TLR4 in obese individuals compared
to healthy controls, while methylation of seven CpGs in the
promoter region of TLR2 was significantly lower in subjects with
T2D compared to obese subjects and normal-weight controls,
which correlated with body mass index (BMI) (52). Furthermore,
distinct changes in gut microbiota composition were observed
between the three groups, the most significant being a high
abundance of lactic acid bacteria in individuals with T2D.
Gut microbiota contribute to energy metabolism through the
production of short chain fatty acids (SCFA) during fermentation
in the colon. SCFAs are believed to alter DNA methylation
patterns of genes involved in inflammatory reactions, including
genes encoding free fatty acid receptors (FFARs) (77, 78).
Based on this as well as their previous findings, a follow up
study conducted by Remely et al. investigated the effect of
gut microbiota and SCFA production on DNA methylation of
FFAR3 in blood from the same cohort described previously
(52). Their results showed differential composition of gut
microbiota in the T2D and obese subjects, and significantly
higher methylation in five CpGs in the FFAR3 promoter region
in normal-weight controls compared to obese subjects with the
lowest methylation in subjects with T2D (77). Taken together,
these two studies provide evidence that differential composition
of gut microbiota in obesity and T2D is associated with epigenetic
gene regulation. The authors thus proposed that improvements
in diet targeted to restore gut microbial balance may ameliorate
aberrant epigenetics and be effective as a preventative treatment
for metabolic syndrome (52).
GENOME-WIDE ASSOCIATION STUDIES
With technological advances, the focus of epigenetics studies
has shifted from candidate regions to high throughput, genome
wide association studies (GWAS). In the past few years, as a
result of a widespread use of techniques, including the Infinium
Beadchip Arrays and methylation pull-down sequencing assays,
major insights into DNA methylation changes associated with
T2D have been obtained, which are summarized in Table 3.
Microarray-based Methylation Assays
Microarray-based methylation assays use the ratio between
hybridization intensities of DNA samples before and after
digestion with a cocktail of methyl-sensitive restriction enzymes
to generate quantitative methylation scores (91). This technique
was used in one of the first GWAS to compare T2D-associated
genome-wide methylation alterations in human blood. Toperoff
et al. assessed pooled, peripheral blood DNA methylation in
a Jewish cohort of 710 T2D and 459 control subjects (79).
Their analysis covered 1 461 753 DNA genomic fragments
containing 3,359,645 CpG methylation sites and results showed
that differentially methylated sites were enriched in genomic
regions that had previously been associated with T2D. The most
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significant methylation differences between T2D and control
subjects mapped to the SLC30A8, TCF7L2, FTO, potassium
voltage-gated channel subfamily KQT member 1 (KCNQ1),
thyroid adenoma associated protein (THADA), and juxtaposed
with another zinc finger protein 1 (JAZF1) genes (79). The authors
validated these methylation changes using bisulfite sequencing,
which also revealed that hypomethylation of a CpG site in the
first intron of the FTO gene, was significantly associated with
T2D risk. Furthermore, these findings were reproduced by the
same group in an independent population cohort (Jerusalem LRC
longitudinal Study) of young individuals who later developed
T2D, indicating that hypomethylation of specific genomic sites
may be an early risk factor that predisposes individuals to T2D
later in life.
Beadchip Arrays
Bead array-based DNA methylation analysis is designed to
provide single-base resolution and quantitative evaluation of
specific cytosines in multiple samples (92). The Infinium
HumanMethylation BeadChip was developed by Illumina
and interrogates over 485,000 methylation sites and covers
96% of CpG islands, as well as additional island shores (i
e., regions flanking 2 kb of CpG islands) (93). Using the
HumanMethylation450 BeadChip, Chambers et al. investigated
T2D-associated DNAmethylation alterations in peripheral blood
from 2,664 Indian Asians and replicated the study findings in
1,141 Europeans (80). Differentially methylated CpG sites were
identified within 853 genes in individuals with T2D, including
known T2D-associated loci, TCF7L2, FTO, and KCNQ1. The
authors also found that CpG sites in thioredoxin-interacting
protein (TXNIP), ATP-binding cassette sub-family G member
1 (ABCG1), phosphoethanolamine/phosphocholine phosphatase 1
(PHOSPHO1), suppressor of cytokine signaling 3 (SOCS3), and
sterol regulatory element-binding transcription factor 1 (SREBF1)
were significantly associated with the future development of T2D
(80). In addition, the combined methylation scores for these five
loci were associated with future T2D incidence independently of
the established T2D risk factors—family history of T2D, physical
activity, BMI, waist:hip ratio, HbA1c, and glucose and insulin
concentrations.
The loci identified by the Chambers study were later evaluated
in an independent cohort (the Botnia prospective study) by
Dayeh et al. (81), who confirmed an association between ABCG1
and PHOSPHO1 methylation in whole blood and future T2D
risk but not SOCS3, SREBF1, or TXNIP. They found that ABCG1
hypermethylation positively associated with HbA1c and fasting
insulin levels. Furthermore, the methylation status of ABCG1
could be replicated in the blood of diabetic twins compared to
their non-diabetic counterparts (81). The association between
ABCG1 hypermethylation and fasting blood glucose and insulin
levels has also been reported in three other GWAS studies (82–
85). The ABCG1 gene encodes a protein involved in cholesterol
transport (94). Since cholesterol abnormalities is a hallmark of
T2D, it is tempting to speculate that hypermethylation of this
gene may modulate circulating cholesterol levels, and thus have
an impact on initiation and progression of T2D, as well as
T2D-associated cardiovascular complications (94).
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Dayeh et al. also found that DNA hypermethylation at the
PHOSPHO1 locus positively correlated with HDL and associated
with decreased T2D risk (81). The PHOSPHO1 gene encodes
a hydrolase enzyme and is involved in skeletal and vascular
mineralization (95, 96). Cardiovascular calcification is a common
consequence of aging, diabetes and hypercholesterolemia, and
PHOSPHO1 has thus been marked as an attractive target for
cardiovascular therapy (96). The observation that PHOSPHO1
hypermethylation correlated with HDL and reduced T2D risk
provides additional evidence for its candidacy as a diagnostic
marker for T2D–associated CVD complications.
Muftah et al. investigated DNA methylation patterns in the
whole blood of 123 subjects from an Arab cohort and replicated
eight known CpG associations with T2D/BMI identified in
Caucasians, including an association of TXNIP hypomethylation
with T2D (reported by the Chambers study) (19, 80).
Hypomethylation of TXNIP in T2D subjects has since been
reported in four additional studies using HumanMethylation450
BeadChip arrays (84–87). Interestingly, TXNIP expression is
induced by glucose, as a result of a carbohydrate response
element in its promoter and TXNIP overexpression has been
reported in both diabetic animals and humans (97). Furthermore,
TXNIP has been linked to vascular complications through
its ability to modulate angiogenesis by repressing vascular
endothelial growth factor (VEGF) (97). Muftah et al. also
identified a significant association between methylation at a
novel CpG site within the DEAQ-box RNA dependent ATPase 1
(DQX1) gene and T2D in both the Arab and Caucasian cohorts
(19). DQX1 encodes an RNA-dependent ATPase, which is highly
expressed in the liver and muscle, however its role in T2D
remains to be elucidated (98).
A family-based study by Kulkarni et al. analyzed the
association of DNA methylation at 446,356 sites in peripheral
blood from 850 pedigreed Mexican-American individuals (85).
They found differential methylation of 51 CpG sites that
significantly associated with T2D, 19 with increased fasting
blood glucose concentrations and 24 with HOMA-IR (85).
Interestingly, the five CpG sites that were most significantly
associated with T2D-related traits mapped to three genes,
including the previously identifiedTXNIP andABCG1 genes, and
Sterile Alpha Motif Domain Containing 12 (SAMD12). SAMD12
has been identified as a target of gene fusion in breast cancer (99),
however its role in T2D still needs to be explored.
More recently, Jeon et al. (88) investigated genome-wide
DNA methylation changes in peripheral blood related to
hypoglycaemia in a longitudinal Korean population-based cohort
(88). They identified hypomethylation of two genes, Musashi
RNA-Binding Protein 2 (MSI2) and CXXC-Type Zinc Finger
Protein 4 (CXXC4), in individuals with T2D and impaired glucose
tolerance, compared to healthy controls. They further assessed
these findings in an additional cross-sectional replication cohort
of subjects with T2D and healthy controls, using targeted
pyrosequencing. Here, only MSI2 hypomethylation could be
validated, which significantly associated with T2D. Interestingly,
the same association was observed in pancreatic islet DNA
from subjects with T2D, indicating that MSI2 methylation may
be biologically relevant. This is in line with expression studies
performed by Szabat et al. (100), who demonstrated that MSI2
could be upregulated in response to lipotoxicity and endoplasmic
reticulum (ER) stress, and that knockdown/overexpression of
MSI2 in mouse pancreatic beta cells resulted in significantly
altered insulin expression, suggesting a potential modulatory role
for MSI2 in T2D.
Methylated DNA Immunoprecipitation
Sequencing
Methylated DNA immunoprecipitation sequencing (MeDIP-seq)
is a versatile, unbiased approach for detecting methylated DNA
and involves the use of a monoclonal antibody that specifically
recognizes 5 mC to enrich for methylated DNA, after which
the immunoprecipitated fraction can be analyzed by large-scale
sequencing (101). This approach is particularly useful because
it bypasses the need for bisulfite conversion and is able to
distinguish between 5 mC and 5-hydroxymethylcytosine, an
oxidation product of 5 mC (101).
Yuan et al. (89) investigated epigenome-wide methylation
patterns in whole blood from monozygotic twins discordant
for T2D using MeDIP-sequencing, after which the top scoring
results were replicated in a separate cohort of twins using the
Illumina Human Methylation 450K array. In the first cohort of
twins, they identified T2D-associated differentially methylated
regions located within 3,597 genes, which were hypermethylated
in two-thirds of cases (89). Furthermore, 30% of the differentially
methylated regions could be replicated in the additional twin
cohort. Importantly, the top two differentially hypermethylated
regions identified in the study were found to reside within
a 2 kb region upstream of the transcriptional start site of
the mucosa-associated lymphoid tissue lymphoma translocation
protein 1 (MALT1) gene. Studies in MALT1 knockout mice
have demonstrated its critical roles in antigen- receptor-induced
activation of NF-κB (89). NF-κB has well established roles
in T2D–associated chronic inflammation, however, the effects
of MALT1 hypermethylation or transcript depletion on NF-
κB signaling and associated inflammation in humans has not
yet been explored (102). In the same study, Yuan et al. also
identified hypermethylation in the promoter region of the G-
protein receptor 6 (GPR6) gene, encoding a member of the G
protein-coupled receptor family of transmembrane receptors.
Interestingly, GPR6 knockout mice exhibit hyperphagia-induced
obesity and higher liver triglyceride content, plasma insulin, and
leptin levels compared to wild-type mice (103). These findings
suggest that GPR6 plays a role in the regulation of food intake
and body weight, and may thus be an important molecular target
for obesity or hyperphagia.
Matsha et al. (90) performed GWAS analysis on DNA
methylation patterns in peripheral blood from a small
cohort of South African women of mixed ethnic ancestry,
consisting of 3 subjects with T2D, 3 with pre-diabetes, and
3 with normoglycaemia. They identified 1,415 differentially
methylated sites in the promoter regions of T2D subjects
compared to normoglycaemic controls, of which over 80%
were hypermethylated, including the following genes: B-Cell
CLL/Lymphoma 3 (BCL3), Interleukin 23 Subunit Alpha (IL23A),
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F2R Like Trypsin Receptor 1 (F2RL1), S100 Calcium Binding
Protein A12 (S100A12), TNF Receptor Superfamily Member
10b (TNFRSF10B), NIMA Related Kinase 6 (NEK6), Ring
Finger Protein 31 (RNF31), Solute Carrier Family 35 Member
B2 (SLC35B2), and Interleukin 1 Receptor Associated Kinase 1
Binding Protein 1 (IRAK1BP1). Interestingly, when grouped
according to chromosomal location it was found that, compared
to controls and pre-diabetic subjects, individuals with T2D
had hypermethylated regions that were more common in
chromosomes 3, 6, 11, 13, and 17, while more hypomethylated
methylated regions were found in chromosome 1. Furthermore,
these identified hypermethylated regions mapped to pathways
related to T2D, including cell surface signaling, glucose
transport, insulin signaling, pancreas development, and the
immune system, whereas hypomethylated regions related to
the pro-inflammatory NF-κB cascade, as well as metabolism
pathways for polyunsaturated omega-6 fatty acids, linoleic acid,
and arachidonic acid (90). Interestingly, excess consumption
of polyunsaturated fatty acids, particularly found at high
concentrations in the western diet, can result in increased
inflammation and contribute to the onset of chronic diseases
including obesity and T2D (104). Importantly, Matsha et al. (90)
demonstrated that linoleic acid and arachidonic acid metabolism
pathways were also associated with hypomethylated differentially
methylated regions in subjects with prediabetes compared to
controls, suggesting that alterations in the methylation state of
these genes may occur before the onset of overt T2D.
An additional investigation by the same group focused
on identifying T2D-associated DNA methylation changes in
intergenic regions compared to promoter and gene body regions,
as it now appreciated that methylation within intergenic regions
regulate RNA processing, as well as high-copy interspersed or
tandem DNA repeats (10). Using peripheral blood DNA from
the same South African patient cohort as described above (90),
they showed increased DNA methylation in intergenic regions
compared to gene body and promoter regions (11). Furthermore,
3,081 of the differentially methylated regions were associated
with microRNAs. Importantly, a subset of miRNAs identified
in the study, including miR-9, miR-34, miR-124, and miR-1297,
have already been linked to T2D and associated traits in human
and animal diabetic models. Since dysregulated miRNAs have an
established role in T2D (105), those identified by Pheiffer et al.
merit further evaluation as novel disease risk biomarkers.
INTERACTIONS BETWEEN GENETICS AND
EPIGENETICS IN T2D
There is evidence to suggest that single nucleotide
polymorphisms (SNPs) may be associated with altered epigenetic
signatures (106). Indeed, it has been suggested that up to 25%
of all SNPs in the genome either introduce or remove CpG sites
(106, 107). In this regard, CpG-SNPs have been suggested to be
a potential mechanism through which SNPs affect gene function
via epigenetics, highlighting the complex interaction between
genetics and epigenetics (107). While CpG-SNPs have been
reported in numerous obesity-associated genes, few studies have
examined the association between SNPs and T2D risk through
effects on DNA methylation (108).
An investigation of T2D-associated DNA methylation
candidates reported in this review revealed that 20 genes were
indeed associated with SNPs. FTO, and TCF7L2 have been
deemed two of the most important T2D susceptibility genes
to date (54–57, 109, 110), while additional SNPs in MCP-1,
SLC30A8, GCK, PRKCZ, GIPR, IGFBP-7, PTPN1, PPARγ ,
KCNQ1, BCL11A, CALM2, CRY2, CAMK1D, THADA, ABCG1,
SOCS3, SREBF1, TXNIP have either been associated with
glycaemic traits, T2D or risk of T2D-linked complications
(63, 64, 110–119). It is still unknown whether the above
associated SNPs may directly cause differential DNAmethylation
of genes that contribute to the pathogenesis of T2D, or if SNPs
within regulatory regions change the affinity and/or binding of
transcription factors, which in turn influence the recruitment
of epigenetic machinery. Future work should be directed at
combining genetic information and methylation marks when
comparing individuals with T2D to those without disease.
Interestingly, SNPs may also be associated with altered global
DNA methylation. Matsha et al. performed genetic screening
of polymorphisms in the nitric oxide synthase 3 (NOS3) gene
using peripheral blood from South African subjects with T2D,
pre-diabetes or normoglycaemia, and reported that the NOS3
G894T polymorphism was independently associated with global
DNA methylation. NOS3 has previously been reported to be
affected by supplementation with folate, a dietary methyl donor
(120). Although the potential role played by NOS3 in global
DNA methylation is unclear, it encodes an enzyme involved
in endothelial function and may thus potentially contribute to
T2D-associated vascular complications (121).
CHALLENGES AND LIMITATIONS IN DNA
METHYLATION STUDIES
The current review highlighted variation in the outcome of DNA
methylation studies, however, it is important to note that the
range of methods employed to measure DNAmethylation is vast,
as are the sources of DNA (cell type), DNA isolation method
and methods of data analysis (122). This large heterogeneity
complicates the direct comparison of findings between studies,
particularly for those published more than a decade ago, as
the epigenetics field is expanding at such a rapid rate. The
standardization of experimental and analysis approaches, as well
as internal and external validation of study findings will be an
important step in improving the reproducibility and biological
relevance of these findings.
The inability of some of the reported studies to replicate
methylation associations could be explained by differences
in the groups of participants analyzed, as the majority of
findings emanated from small cross-sectional or case-control
studies in varying populations. To advance reproducibility in
different populations, more robust longitudinal studies are
required, which would involve prospective recruitment of a large
cohort of healthy individuals at baseline, and the follow-up of
these individuals over several decades to track T2D incidence.
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However, due to higher costs and study duration, longitudinal
studies for complex diseases such as T2D still remain scarce.
The only longitudinal studies reported in this review were that
of Chambers et al. (80) and Jeon et al. (88). Interestingly,
differentially methylated genes identified in the Chambers study
were replicated in cross-sectional studies (TXNIP, ABCG1,
PHOSPHO1, and SREBF1) (19, 81–87). The ability of these
changes to be captured across studies of different time lengths
may be attributed to the stable nature of DNAmethylation marks
after disease onset.
An additional limitation in some of the reported studies was
failure to include in-depth demographic, lifestyle, and health
data and consequently, lack of consideration or adjustment
for potential confounding factors. This is crucial for data
interpretation as it is now widely appreciated that DNA
methylation signatures vary with gender, age, and ethnicity
and are sensitive to many environmental influences (32).
Indeed, in cases where gender was considered, differences in
DNA methylation patterns were reported for BCL11A, GCK,
IGFBP-7, and PTPN1 (44, 46, 49). These observations are
consistent with findings on gender-specific DNA methylation
marks in other diseases, such as PLA2G7 in cardiovascular
disease and MTHFR in schizophrenia (123, 124). Furthermore,
gender-specific differences in glucose homeostasis and T2D
risk have been reported, which may be related to the
levels of sex-hormones such as estrogen and testosterone
(125). The confounding effect of chronic medication was also
highlighted by Matsha et al. (30), who reported an association
between global DNA hypomethylation in T2D individuals
and the use of glucose-controlling agents. Indeed, the widely
used anti-diabetic drug, metformin, was recently shown to
promote global DNA methylation in cancer cell lines by
modulating the intracellular ratio of S-adenosylhomocysteine
(SAH) and S-adenosylmethionine (SAM) (126). Thus, the
observed methylation differences and associations between
methylation changes and T2D risk might be confounded by
medications, such as metformin, which should be taken into
consideration in future studies. Furthermore, these findings
may offer opportunities for the use of DNA methylation for
monitoring of management and response to T2D medications.
DNA methylation varies with cell type and thus cellular
homogeneity within a tissue is an important characteristic for a
DNA methylation biomarker. While the finding in this review
strengthen the candidacy of blood-based markers, it is important
to note that blood exhibits cellular heterogeneity, as it consists
of a wide variety of cell types including erythrocytes, basophils,
neutrophils, eosinophils, monocytes, lymphocytes, natural killer
cells, and platelets (127). Each of these cells possess a unique
epigenetic signature and this can lead to variation between
studies. Only one study reported in this review controlled for
the estimated proportion of different blood cell types, and
indeed proved that epigenetic heterogeneity in whole blood cell
constituents impacts on data interpretation (31). Thus, it is
plausible that differences in cell composition between groupsmay
drive false associations or mask potential differences between
groups. In this regard, there are several additional methods that
can be used to avoid potential confounding effects of the blood
cell composition, such as the measurement of DNA methylation
in individual cell types following sorting of the cells, adjustment
for direct measured cell count or the use of post-hoc regression
models, as described by Houseman et al. (128).
It is important to note that while DNA methylation in gene
promoters has consistently been linked with gene silencing, some
studies could not correlate promoter methylation with gene or
protein expression (49). This could either be a result of DNA
methylation at the reported CpGs being ineffective to reduce
transcript levels, or due to alternative transcriptional or post-
transcriptional influences. Indeed, a growing body of evidence
suggests that miRNAs and histone modifications are also highly
involved in T2D pathogenesis, for which comprehensive reviews
have been published (105, 129, 130).
CONCLUSIONS AND FUTURE
PERSPECTIVES
The current review identified 37 articles investigating DNA
methylation markers for T2D detection or risk evaluation,
using DNA isolated from blood. Based on reproducible findings
from the reviewed studies in different population groups,
differentially methylated sites in TCF7L2, KCNQ1, ABCG1,
TXNIP, PHOSPHO1, SREBF1, SLC30A8, and FTO are potentially
associated with T2D and their predictive powers may hold
irrespective of different genetic backgrounds and different
lifestyle or environmental pressures. A model for the role
of these DNA methylation alterations in the pathogenesis of
T2D is depicted in Figure 1. Although these alterations were
FIGURE 1 | Model proposing a role for DNA methylation in the pathogenesis
of Type 2 Diabetes and its interaction with environmental factors and genetics.
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detected in blood, which is not an insulin-responsive tissue,
the implicated genes have been shown to play a role in
critical biological processes that are deregulated during T2D
development, including energy intake and expenditure (FTO),
lipogenesis and glycolysis (SREBF1), glucose homeostasis and
carbohydrate metabolism (TXNIP, TCF7L2), lipid transport
(ABCG1) pancreatic insulin secretion (SLC30A8, KCNQ1), and
cardiovascular function (PHOSPHO1). It is thus plausible
that these blood-based epigenetic markers mirror tissues with
deteriorated metabolic function, and are prime non-invasive
candidates for T2D biomarkers.
Some limitations of the current review are the exclusion of
studies that were not published in English and the use of only
four databases of published literature. Positive publication bias
also should be considered, as studies with negative findings may
not have been published. Finally, the current review only focused
on DNA methylation, given the large scope of studies already
published in this field. Although it was beyond the scope of this
review, we cannot rule out other possible epigenetic biomarker
candidates of T2D, such as non-coding RNAs and histone
modifications, for which evidence is rapidly accumulating (105,
129, 130).
The major strength of this review is the central focus on
blood-based DNA methylation signatures in T2D, which will
have important implications for the development of non-invasive
T2D screening tests, given the difficulty in accessing T2D-
associated tissues, particularly for longitudinal studies. To the
best of our knowledge, this is the only review solely examining
associations of T2D with DNAmethylation profiles in peripheral
blood. We also highlighted specific methylation patterns that
associated with T2D risk factors such as BMI, HbA1c levels, and
HDL/LDL, which further supports the hypothesis that profiling
DNA methylation in blood could be used to monitor high
risk individuals and delay or prevent T2D by facilitating early
intervention strategies. In this regard, the candidate markers in
this review need to be further validated in additional prospective
study cohorts and tested in large screening populations by high
quality studies. At present, no epigenetic biomarkers for T2D
have yet entered clinical trials, however, there is hope that
initiatives such as next generation sequencing and the use of
longitudinal study designs, will uncover important predictive
T2D biomarkers.
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